Erratum to: A phase I/II study of ofatumumab (GSK1841157) in Japanese and Korean patients with relapsed or refractory B-cell chronic lymphocytic leukemia

Excerpt

A published-ahead-of-print version of this article was made available online on 12 July 2013. It was subsequently determined that the reported drug concentration measurements were from a manner which deviated from the Standard Operation Procedures (SOP) in place at the time of sample analysis. This deviation involved an enzyme-linked immunosorbent assay (ELISA) which was used for measurement of plasma ofatumumab concentrations in Study OMB112758, involving 45 samples on one specific immunoassay plate among a total of 307 samples in this study. Re-measurement of these impacted samples was performed in compliance with the current SOP, and the pharmacokinetic parameters were re-calculated. The correct data and figure appear below. This substitution of data does not impact on any scientific findings and outcomes, logic of discussion and the conclusion of the manuscript. The authors wish to apologize to readers and editorial office for any inconvenience this might cause. …